The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback